TELA Bio (TELA) to Release Quarterly Earnings on Thursday

TELA Bio (NASDAQ:TELAGet Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, March 21st. Analysts expect TELA Bio to post earnings of ($0.44) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

TELA Bio Price Performance

TELA opened at $5.55 on Thursday. The firm has a market cap of $135.91 million, a price-to-earnings ratio of -2.69 and a beta of 0.97. TELA Bio has a fifty-two week low of $4.23 and a fifty-two week high of $11.65. The company’s 50-day moving average price is $6.86 and its 200 day moving average price is $6.70. The company has a quick ratio of 4.43, a current ratio of 5.36 and a debt-to-equity ratio of 1.32.

Analysts Set New Price Targets

Separately, Lake Street Capital reiterated a “buy” rating and set a $14.00 price objective on shares of TELA Bio in a research note on Wednesday, December 27th.

View Our Latest Analysis on TELA

Institutional Investors Weigh In On TELA Bio

Large investors have recently made changes to their positions in the company. Barclays PLC acquired a new stake in shares of TELA Bio in the second quarter valued at approximately $33,000. California State Teachers Retirement System acquired a new stake in shares of TELA Bio in the second quarter valued at approximately $53,000. Morgan Stanley increased its stake in shares of TELA Bio by 38,708.3% in the fourth quarter. Morgan Stanley now owns 4,657 shares of the company’s stock valued at $54,000 after purchasing an additional 4,645 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of TELA Bio by 8,294.9% in the second quarter. Wells Fargo & Company MN now owns 6,632 shares of the company’s stock valued at $67,000 after acquiring an additional 6,553 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of TELA Bio in the second quarter valued at approximately $83,000. Institutional investors and hedge funds own 91.06% of the company’s stock.

TELA Bio Company Profile

(Get Free Report)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

See Also

Earnings History for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.